Cytoreductive surgery for synchronous and metachronous colorectal peritoneal dissemination: Japanese P classification and peritoneal cancer index

[1]  Yong Li,et al.  Development and Validation of a Prognostic Nomogram for Colorectal Cancer Patients With Synchronous Peritoneal Metastasis , 2021, Frontiers in Oncology.

[2]  K. Sugihara,et al.  Investigation of the Japanese Classification of Peritoneal Metastasis from Colorectal Cancer Referring to the Correlation with PCI , 2020, Journal of the anus, rectum and colon.

[3]  Z. Wang,et al.  High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy , 2020, BMC cancer.

[4]  K. Sugihara,et al.  Factors affecting R0 resection of colorectal cancer with synchronous peritoneal metastases: a multicenter prospective observational study by the Japanese Society for Cancer of the Colon and Rectum , 2019, International Journal of Clinical Oncology.

[5]  大腸癌研究会.  Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English Edition [Secondary Publication] , 2019, Journal of the anus, rectum and colon.

[6]  J. Briceño-Delgado,et al.  Colorectal peritoneal metastases: Optimal management review , 2019, World journal of gastroenterology.

[7]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.

[8]  Lynette M. Smith,et al.  Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures , 2019, JAMA network open.

[9]  D. Morris,et al.  Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. , 2016, Anticancer research.

[10]  A. Govindarajan,et al.  Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy , 2015, Clinics in Colon and Rectal Surgery.

[11]  K. Sugihara,et al.  Enhancing the objectivity of the Japanese classification of peritoneal metastases from colorectal cancer. , 2014, Japanese journal of clinical oncology.

[12]  A. Mirnezami,et al.  Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone , 2014, British Journal of Cancer.

[13]  Y. Yonemura,et al.  Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy , 2013, TheScientificWorldJournal.

[14]  C. Germer,et al.  Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades , 2013, British Journal of Cancer.

[15]  F. Granath,et al.  Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer , 2012, The British journal of surgery.

[16]  P. Sugarbaker.  Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[17]  Mbbs Mrcs Kathryn Waite BSc,et al.  The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review , 2016, Annals of Surgical Oncology.

[18]  Shung-Haur Yang,et al.  CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. , 2002, Hepato-gastroenterology.

[19]  P. Sugarbaker,et al.  Successful management of microscopic residual disease in large bowel cancer , 1999, Cancer Chemotherapy and Pharmacology.